RESUMEN
The differential diagnosis of vesiculobullous lesions can be intimidating to the primary care provider. While some entities such as bullous impetigo may easily be diagnosed clinically if the patient's demographics as well as the lesion morphology and distribution present classically, atypical presentations may require additional laboratory studies for confirmation. We describe a case of bullous impetigo with characteristics that clinically mimicked two rare immunobullous dermatoses. Although extensive diagnostic testing was performed, we recommend an approach for primary care providers to initiate empiric treatment while maintaining awareness of less common immunobullous entities.
Asunto(s)
Impétigo , Enfermedades Cutáneas Vesiculoampollosas , Traumatismos de los Tejidos Blandos , Humanos , Impétigo/diagnóstico , Impétigo/patología , Enfermedades Cutáneas Vesiculoampollosas/diagnóstico , Enfermedades Cutáneas Vesiculoampollosas/patología , Diagnóstico DiferencialRESUMEN
Pustular psoriasis of pregnancy (PPP) also known as impetigo herpetiformis is a well-described dermatosis of pregnancy characterized by the fatal progression of disease for both the mother and the foetus if left untreated. A 28-year-old G2P1L1 pregnant mother at 28 weeks of gestation, came to outpatient department (OPD) with complaints of scaly skin lesions all over her body along with fever, nausea and generalised weakness. On examination, there were erythematous scaly patches in the trunk, back, hands and legs accompanied by formation of pustules in the periphery of the lesions. Histopathological examination was consistent with pustular psoriasis. Patient was managed with prednisolone (40 mg/day which was later tapered). Serial antenatal visits and ultrasounds were done to monitor the health of the mother and foetal growth. Under the support of obstetrician, patient delivered a healthy female baby through caesarean section under general anaesthesia. Her lesions persisted in the postpartum period, which later started reducing gradually.
Asunto(s)
Dermatitis Herpetiforme , Impétigo , Psoriasis , Enfermedades Cutáneas Vesiculoampollosas , Humanos , Embarazo , Femenino , Adulto , Impétigo/complicaciones , Impétigo/diagnóstico , Impétigo/patología , Dermatitis Herpetiforme/diagnóstico , Cesárea , Psoriasis/diagnóstico , Psoriasis/tratamiento farmacológico , Piel/patología , Enfermedades Cutáneas Vesiculoampollosas/patologíaAsunto(s)
Vesícula/microbiología , Vesícula/patología , Impétigo/diagnóstico , Impétigo/patología , Antibacterianos/uso terapéutico , Cefaclor/uso terapéutico , Preescolar , Ácido Fusídico/uso terapéutico , Humanos , Iminas/uso terapéutico , Impétigo/complicaciones , Impétigo/tratamiento farmacológico , Masculino , Piridinas/uso terapéutico , Crema para la PielRESUMEN
Ecthyma gangrenosum (EG) is a potentially lethal skin infection, most commonly due to Pseudomonas aeruginosa with bacteremic dissemination and affecting mostly immunocompromised patients. We present two cases of EG in two men in Belgium recently admitted to our hospital, caused by a suspected coinfection by group A Streptococcus and Staphylococcus aureus, with a cutaneous dissemination, in which multiple impetigo lesions were the portal of entry. The first patient had no risk factors nor immunodeficiency, but the second was a homeless man with drug and alcohol abuse and advanced HIV infection. Early management of the condition is crucial, with initial broad spectrum antibiotherapy, rapidly narrowed down to the germs identified and skin lesion debridement if necessary. Any immunocompromising condition must be ruled out in any patient suffering from EG.
Asunto(s)
Ectima/microbiología , Gangrena/microbiología , Piel , Staphylococcus aureus , Streptococcus pyogenes , Adulto , Bélgica , Coinfección , Ectima/diagnóstico , Ectima/patología , Gangrena/diagnóstico , Gangrena/patología , Humanos , Impétigo/diagnóstico , Impétigo/microbiología , Impétigo/patología , Masculino , Piel/microbiología , Piel/patologíaAsunto(s)
Impétigo , Síndrome Estafilocócico de la Piel Escaldada , Niño , Preescolar , Humanos , Impétigo/diagnóstico , Impétigo/etiología , Impétigo/patología , Impétigo/terapia , Lactante , Pediatría , Síndrome Estafilocócico de la Piel Escaldada/diagnóstico , Síndrome Estafilocócico de la Piel Escaldada/etiología , Síndrome Estafilocócico de la Piel Escaldada/patología , Síndrome Estafilocócico de la Piel Escaldada/terapiaAsunto(s)
Eliminación de Componentes Sanguíneos , Proteínas Adaptadoras de Señalización CARD/genética , Guanilato Ciclasa/genética , Impétigo/genética , Proteínas de la Membrana/genética , Complicaciones Infecciosas del Embarazo/genética , Piel/patología , Adulto , Femenino , Humanos , Impétigo/patología , Impétigo/terapia , Embarazo , Complicaciones Infecciosas del Embarazo/patología , Complicaciones Infecciosas del Embarazo/terapiaRESUMEN
Wolf's isotopic response refers to the occurrence of a new skin disease at the exact site of an unrelated skin disease that had previously healed. Various cutaneous lesions have been described after herpes zoster. This study included 24 patients with Wolf's isotopic response after herpes zoster infection, which presented as manifestations ranging from inflammatory disease to carcinoma. Histopathological examinations in 12 patients and immunohistochemical analyses in 10 patients allowed exploration of secondary microscopic changes in the lesions. CD4+/CD8+ T-cell ratios were normal and infiltrating cells included mast cells, eosinophils, and tumour cells. Our study has described additional patients with confirmed Wolf's isotopic response following herpes zoster infection; moreover, it has extended the spectrum of Wolf's isotopic response to include impetigo. We suggest Wolf's isotopic response classification categories for herpes zoster-associated Wolf's isotopic response. Additionally, clinicians should consider the possibilities of different diseases in Wolf's isotopic response, especially malignancies.
Asunto(s)
Herpes Zóster/virología , Herpesvirus Humano 3/patogenicidad , Enfermedades de la Piel/inmunología , Piel/inmunología , Adulto , Anciano , Dermatitis/inmunología , Dermatitis/patología , Femenino , Herpes Zóster/inmunología , Herpes Zóster/patología , Humanos , Impétigo/inmunología , Impétigo/patología , Masculino , Persona de Mediana Edad , Pronóstico , Piel/patología , Piel/virología , Enfermedades de la Piel/patología , Enfermedades de la Piel/cirugía , Neoplasias Cutáneas/inmunología , Neoplasias Cutáneas/patología , Adulto JovenRESUMEN
Acute generalised exanthematous pustulosis (AGEP) is a severe cutaneous adverse reaction characterised by the appearance of erythematous plaques and papules with overlying non-follicular pinpoint pustules. Drugs are the cause of AGEP in approximately 90% of cases. The most common causes include anti-infective agents (aminopenicillins, quinolones, antibacterial sulfonamides and terbinafine), antimalarials and diltiazem. To the best of our knowledge, to date there has only been one report of hydrochlorothiazide-induced AGEP. There has never been a case report of losartan-induced AGEP. Here, we present a case of AGEP that is the second case purportedly caused by hydrochlorothiazide.
Asunto(s)
Pustulosis Exantematosa Generalizada Aguda/patología , Antiinfecciosos/efectos adversos , Oftalmopatías/tratamiento farmacológico , Hidroclorotiazida/efectos adversos , Impétigo/tratamiento farmacológico , Pustulosis Exantematosa Generalizada Aguda/tratamiento farmacológico , Administración Tópica , Anciano de 80 o más Años , Antiinfecciosos/uso terapéutico , Betametasona/uso terapéutico , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Oftalmopatías/patología , Femenino , Glucocorticoides/uso terapéutico , Humanos , Hidroclorotiazida/uso terapéutico , Impétigo/patología , Metoprolol/uso terapéutico , Resultado del TratamientoRESUMEN
Sphingosine 1-phosphate (S1P) is a bioactive lipid mediator generated when a cell membrane or its components are damaged by various factors. S1P regulates diverse cell activities via S1P receptors (S1PRs). Keratinocytes express S1PR1-5. Although it is known that S1PRs control keratinocyte differentiation, apoptosis, and wound healing, S1PR functions in keratinocyte infections have not been fully elucidated. We propose that the S1P-S1PR axis in keratinocytes works as a biosensor for bacterial invasion. Indeed, in human impetigo infection, we found high epidermal expression of S1PR1 and S1PR2 in the skin. Furthermore, in normal human epidermal keratinocytes in vitro, treatment with Staphylococcus aureus bacterial supernatant not only induced S1P production but also increased the transcription of S1PR2, confirming our in vivo observation, as well as increased the levels of TNFA, IL36G, IL6, and IL8 mRNAs. However, direct treatment of normal human epidermal keratinocytes with S1P increased the expressions of IL36G, TNFA, and IL8, but not IL6. In both S1P- and S. aureus bacterial supernatant-treated normal human epidermal keratinocytes, S1PR1 knockdown reduced IL36G, TNFA, and IL8 transcription, and the S1PR2 antagonist JTE013 blocked the secretion of these cytokines. Overall, we have proven that during infections, keratinocytes communicate damage by using S1P release and tight control of S1PR1 and 2.
Asunto(s)
Interacciones Huésped-Patógeno/inmunología , Impétigo/inmunología , Queratinocitos/inmunología , Lisofosfolípidos/metabolismo , Piel/inmunología , Esfingosina/análogos & derivados , Células Cultivadas , Citocinas/inmunología , Citocinas/metabolismo , Técnicas de Silenciamiento del Gen , Humanos , Impétigo/microbiología , Impétigo/patología , Queratinocitos/metabolismo , Queratinocitos/microbiología , Cultivo Primario de Células , Pirazoles/farmacología , Piridinas/farmacología , Transducción de Señal/efectos de los fármacos , Transducción de Señal/genética , Transducción de Señal/inmunología , Piel/citología , Piel/patología , Esfingosina/metabolismo , Receptores de Esfingosina-1-Fosfato/antagonistas & inhibidores , Receptores de Esfingosina-1-Fosfato/genética , Receptores de Esfingosina-1-Fosfato/metabolismo , Staphylococcus aureus/inmunologíaRESUMEN
Impetigo herpetiformis is a rare disease of pregnancy with the onset being in the second half of pregnancy and resolution after delivery. It is associated with a high rate of perinatal mortality and fetal abnormalities. Clinical and histological features of the disease are consistent with pustuler psoriasis. We reported a case of 25-year-old female gravida 1 para 0, who responded poorly to consecutive treatments with systemic steroids, cyclosporine, intravenous immunoglobulin, and acitretin. Good response was obtained with adding infliximab to the treatment.
Asunto(s)
Dermatitis Herpetiforme/tratamiento farmacológico , Impétigo/tratamiento farmacológico , Infliximab/uso terapéutico , Complicaciones Infecciosas del Embarazo/tratamiento farmacológico , Adulto , Dermatitis Herpetiforme/patología , Fármacos Dermatológicos/administración & dosificación , Fármacos Dermatológicos/uso terapéutico , Quimioterapia Combinada , Femenino , Humanos , Impétigo/patología , Infliximab/administración & dosificación , Embarazo , Complicaciones Infecciosas del Embarazo/patología , Resultado del TratamientoAsunto(s)
Adalimumab/administración & dosificación , Dermatitis Herpetiforme/terapia , Impétigo/terapia , Complicaciones del Embarazo/terapia , Brote de los Síntomas , Adulto , Dermatitis Herpetiforme/diagnóstico , Dermatitis Herpetiforme/patología , Esquema de Medicación , Femenino , Humanos , Impétigo/diagnóstico , Impétigo/patología , Inyecciones Subcutáneas , Procedimientos de Reducción del Leucocitos , Periodo Posparto , Embarazo , Complicaciones del Embarazo/diagnóstico , Complicaciones del Embarazo/patología , Resultado del TratamientoRESUMEN
Ozenoxacin is a novel topical antibacterial agent with potent bactericidal activity against Gram-positive bacteria that has been developed as a 1% cream for treatment of impetigo. This article presents pooled results of pivotal clinical trials of ozenoxacin with the objective of evaluating the efficacy, safety, and tolerability of ozenoxacin 1% cream after twice-daily topical treatment for 5 days in patients with impetigo. A pooled analysis was performed of individual patient data from two multicenter, randomized, double-blind, vehicle-controlled phase 3 registration studies conducted in patients with impetigo. Both clinical trials followed a similar methodology. Patients were randomized 1:1 to ozenoxacin or vehicle. One trial included retapamulin as an internal control. Efficacy was measured using the Skin Infection Rating Scale and microbiological culture. Safety and tolerability were evaluated. Ozenoxacin demonstrated superior clinical success versus vehicle after 5 days of therapy, superior microbiological success versus vehicle after 2 days of therapy, and was safe and well-tolerated. Ozenoxacin showed superior clinical and microbiological response versus vehicle in children as young as 2 months of age, and adults, with impetigo. Clinical Trial Registration: ClinicalTrials.gov identifier: NCT01397461 and NCT02090764; European Clinical Trials Database Number: 2011-003032-31 and 2014-000228-52. J Drugs Dermatol. 2018;17(10):1051-1057.
Asunto(s)
Aminopiridinas/uso terapéutico , Antibacterianos/uso terapéutico , Impétigo/tratamiento farmacológico , Quinolonas/uso terapéutico , Administración Cutánea , Adolescente , Adulto , Anciano , Aminopiridinas/administración & dosificación , Antibacterianos/administración & dosificación , Niño , Preescolar , Método Doble Ciego , Esquema de Medicación , Europa (Continente) , Femenino , Humanos , Impétigo/microbiología , Impétigo/patología , Lactante , Masculino , Persona de Mediana Edad , Quinolonas/administración & dosificación , Ensayos Clínicos Controlados Aleatorios como Asunto , Federación de Rusia , Índice de Severidad de la Enfermedad , Sudáfrica , Resultado del Tratamiento , Estados Unidos , Adulto JovenRESUMEN
Impetigo is a bacterial infection of the superficial layer of the epidermis with crusting or bullae caused by Streptococcus spp., Staphylococcus spp., or both. A 14-yr-old red-tailed monkey ( Cercopithecus ascanius) presented with recurrent scabbing and ulceration under the nares over an 8-yr period. Repeated cultures and biopsy samples led to a presumptive diagnosis of impetigo, later confirmed on necropsy. Multiple antibiotic regimens were employed with varying success during multiple episodes, while lesions resolved on their own at other times. This condition has not been previously reported in a nonhuman primate, although it is not uncommon in humans.
Asunto(s)
Cercopithecus , Impétigo/veterinaria , Enfermedades de los Monos/microbiología , Animales , Femenino , Impétigo/tratamiento farmacológico , Impétigo/patología , Masculino , Enfermedades de los Monos/tratamiento farmacológico , Enfermedades de los Monos/patologíaRESUMEN
Impetigo herpetiformis (pustular psoriasis of pregnancy) is a rare dermatosis of pregnancy that typically starts in the 2nd half of pregnancy and resolves postpartum. It may recur in subsequent pregnancies. I present a case of 23 year old female gravida 4 para 3 with recurrent impetigo herpetiformis at 26 weeks gestation. She presented with a one month history of pustular lesions which responded to treatment with prednisone. She delivered at term with a favourable outcome. The disease resolved one month postpartum. This was the second recurrence of the disease. She had her first episode of impetigo herpetiformis during the second pregnancy. The disease recurred in the 3rd pregnancy and resulted in a still birth.
Asunto(s)
Dermatitis Herpetiforme/patología , Impétigo/patología , Complicaciones Infecciosas del Embarazo/patología , Resultado del Embarazo , Femenino , Humanos , Embarazo , Recurrencia , Adulto JovenRESUMEN
A 2240 gram boy was born at 33.2 weeks gestation with nonblanching, deeply erythematous plaques and papules on the back, flanks, and scalp (Figure 1). His mother was GBS positive and on antibiotic suppression for prior cutaneous MRSA and urinary tract infections. Intrapartum intravenous Penicillin G was administered, and the amniotic sac was artificially ruptured 4 hours prior to delivery to facilitate labor. The delivery was uncomplicated without concern for chorioamnionitis, but the patient initially required CPAP for respiratory distress with 1-minute and 5-minute Apgar scores of 7 and 8, respectively. A skin punch biopsy is shown (Figure 2).
Asunto(s)
Antibacterianos/uso terapéutico , Impétigo/patología , Recien Nacido Prematuro , Complicaciones Infecciosas del Embarazo/tratamiento farmacológico , Infecciones Estreptocócicas/transmisión , Puntaje de Apgar , Biopsia con Aguja , Femenino , Estudios de Seguimiento , Edad Gestacional , Humanos , Inmunohistoquímica , Impétigo/congénito , Impétigo/tratamiento farmacológico , Recién Nacido , Masculino , Embarazo , Complicaciones Infecciosas del Embarazo/microbiología , Síndrome de Dificultad Respiratoria del Recién Nacido/fisiopatología , Síndrome de Dificultad Respiratoria del Recién Nacido/terapia , Infecciones Estreptocócicas/tratamiento farmacológico , Resultado del TratamientoRESUMEN
Group A streptococci (GAS) are highly prevalent human pathogens whose primary ecological niche is the superficial epithelial layers of the throat and/or skin. Many GAS strains with a strong tendency to cause pharyngitis are distinct from strains that tend to cause impetigo; thus, genetic differences between them may confer host tissue-specific virulence. In this study, the FbaA surface protein gene was found to be present in most skin specialist strains but largely absent from a genetically related subset of pharyngitis isolates. In an ΔfbaA mutant constructed in the impetigo strain Alab49, loss of FbaA resulted in a slight but significant decrease in GAS fitness in a humanized mouse model of impetigo; the ΔfbaA mutant also exhibited decreased survival in whole human blood due to phagocytosis. In assays with highly sensitive outcome measures, Alab49ΔfbaA was compared to other isogenic mutants lacking virulence genes known to be disproportionately associated with classical skin strains. FbaA and PAM (i.e., the M53 protein) had additive effects in promoting GAS survival in whole blood. The pilus adhesin tip protein Cpa promoted Alab49 survival in whole blood and appears to fully account for the antiphagocytic effect attributable to pili. The finding that numerous skin strain-associated virulence factors make slight but significant contributions to virulence underscores the incremental contributions to fitness of individual surface protein genes and the multifactorial nature of GAS-host interactions.
Asunto(s)
Proteínas Bacterianas/genética , Proteínas Portadoras/genética , Regulación Bacteriana de la Expresión Génica , Infecciones Estreptocócicas/microbiología , Streptococcus pyogenes/genética , Streptococcus pyogenes/patogenicidad , Animales , Proteínas Bacterianas/metabolismo , Células Sanguíneas/inmunología , Células Sanguíneas/microbiología , Proteínas Portadoras/metabolismo , Modelos Animales de Enfermedad , Fructosa-Bifosfato Aldolasa , Aptitud Genética , Interacciones Huésped-Patógeno , Humanos , Impétigo/inmunología , Impétigo/microbiología , Impétigo/patología , Ratones , Faringitis/inmunología , Faringitis/microbiología , Faringitis/patología , Faringe/inmunología , Faringe/microbiología , Faringe/patología , Isoformas de Proteínas/genética , Isoformas de Proteínas/metabolismo , Piel/inmunología , Piel/microbiología , Piel/patología , Infecciones Estreptocócicas/inmunología , Infecciones Estreptocócicas/patología , Streptococcus pyogenes/metabolismo , VirulenciaRESUMEN
BACKGROUND: Bullous impetigo is a superficial skininfection caused by Staphylococcus aureus (S.aureus). Pyogenic granuloma is a common benigntumor frequently associated with prior trauma.Bullous impetigo and pyogenic granuloma may occurin pregnant women. PURPOSE: The features of a pregnant womanwith pyogenic granuloma and bullous impetigoconcurrently present in a lesion on her finger aredescribed. METHODS: PubMed was used to search the followingterms: bullous impetigo, pregnancy, and pyogenicgranuloma. All papers were reviewed; relevantarticles, along with their references, were evaluatedResults: A red ulcerated nodule with a collaretteof epithelium around the tumor and surroundingbullae appeared on the fifth digit of the left hand of a31-year-old woman who was at 36 weeks gestation. Abacterial culture grew methicillin sensitive S. aureus.An excisional biopsy was performed. Histologicfindings revealed not only a benign vascular tumorwith an infiltrate of mixed inflammatory cells, butalso an intraepidermal blister. She received oralantibiotics and there was complete resolution of thefinger lesion and infection with preservation of digitfunction. CONCLUSION: Albeit uncommon, pyogenic granulomaand bullous impetigo may concurrently occur in thesame lesion. Therapeutic intervention should focuson treating both the benign skin tumor and theinfection.
Asunto(s)
Vesícula/diagnóstico , Granuloma Piogénico/diagnóstico , Dermatosis de la Mano/diagnóstico , Impétigo/diagnóstico , Complicaciones Infecciosas del Embarazo/diagnóstico , Adulto , Antibacterianos/uso terapéutico , Vesícula/complicaciones , Vesícula/tratamiento farmacológico , Vesícula/patología , Femenino , Dedos , Granuloma Piogénico/complicaciones , Granuloma Piogénico/patología , Granuloma Piogénico/cirugía , Dermatosis de la Mano/complicaciones , Dermatosis de la Mano/patología , Dermatosis de la Mano/terapia , Humanos , Impétigo/complicaciones , Impétigo/tratamiento farmacológico , Impétigo/patología , Embarazo , Complicaciones del Embarazo/diagnóstico , Complicaciones del Embarazo/patología , Complicaciones del Embarazo/cirugía , Complicaciones Infecciosas del Embarazo/tratamiento farmacológico , Complicaciones Infecciosas del Embarazo/patología , Tercer Trimestre del Embarazo , Enfermedades de la Piel/complicaciones , Enfermedades de la Piel/diagnóstico , Enfermedades de la Piel/patología , Enfermedades de la Piel/cirugíaRESUMEN
A 10-days-old male neonate presented with multiple bullae, mostly in the diaper region, without signs of illness. We diagnosed this condition as neonatal bullous impetigo and treated the patient orally with flucloxacillin. Bullous impetigo is caused by Staphylococcus aureus toxins that break down intercellular proteins.
Asunto(s)
Vesícula/diagnóstico , Impétigo/diagnóstico , Infecciones Estafilocócicas/diagnóstico , Toxinas Bacterianas , Vesícula/microbiología , Humanos , Impétigo/patología , Recién Nacido , Pierna , Masculino , Infecciones Estafilocócicas/patología , Staphylococcus aureus/químicaRESUMEN
We present the case of a 7-day-old boy with significant, rapidly spreading blistering and desquamation in a "degloving" pattern on the hands that mimicked epidermolysis bullosa but was ultimately diagnosed as bullous impetigo caused by a clinically aggressive strain of Staphylococcus aureus. Bullous impetigo is a desquamating condition caused by local release of S. aureus exfoliative toxin A and is more commonly seen in children. This case highlights the fragility of newborn skin and reviews the major diagnoses that should be considered in an infant with significant blistering.